Table 3.
The change in the average annual rotavirus gastroenteritis hospitalization rate, from the period preceding universal vaccination (2008– 2010) to the period of universal vaccination (2011–2013), by age
| Age (months) | No. AGE hospitalizations | Population size* | Estimated annual incidence rate of AGE hospitalizations (per 1000, 95% CI) | No. rotavirus positive† | Estimated annual incidence rate of RVGE hospitalizations (per 1000, 95% CI) | Estimated no. of AGE hospitalizations, Israel‡ | Estimated no. RVGE hospitalizations Israel‡ | |
|---|---|---|---|---|---|---|---|---|
| 0–11 months | ||||||||
| Annual average: period preceding universal vaccination 2008–2010 | 428 | 12715 | 33.7 (30.1–37.0) | 122 | 9.6 (8.0–11.4) | 5098 | 1444 | |
| Annual average: period of universal vaccination 2011–2013 | 332 | 13510 | 24.6 (22.1–27.3) | 51 | 3.8 (2.9–5.0) | 3994 | 614 | |
| Absolute reduction between the 2 periods | 97 | 795 | 9.1 (5.0–13.2) | 71 | 5.8 (3.9–7.9) | 1103 (230 – 2195)** | 830 (570–1108)** | |
| Percent reduction between the 2 periods§ | 23% | 6.3% growth | 27% (15% – 39%) | 58% | 61% (40% – 82%) | 22% (5% – 39%)** | 58% (52% – 61%)** | |
| 12–23 months | ||||||||
| Annual average pre universal vaccination period 2008–2010 | 363 | 12715 | 28.5 (25.8–32.0) | 156 | 12.3 (10.5–14.3) | 4329 | 1851 | |
| Annual average universal vaccination period 2011–2013 | 238 | 13510 | 17.6 (15.5–20.0) | 66 | 4.9 (3.8–6.2) | 2870 | 797 | |
| Absolute reduction between the pre and universal vaccination periods | 125 | 795 | 10.9 (7.3–14.6) | 90 | 7.4 (5.2–9.7) | 1459 (−17 − 2275)** | 1053 (470 –1523)** | |
| Percent reduction between the pre and universal vaccination periods§ | 35% | 6.3% growth | 38% (26% – 51%) | 58% | 60% (42% – 79%) | 34% (0% – 45%)** | 57% (38% – 67%)** | |
| 24–59 months | ||||||||
| Annual average pre universal vaccination period 2008–2010 | 285 | 38145 | 7.5 (6.7–8.4) | 83 | 2.2 (1.8–2.7) | 3397 | 979 | |
| Annual average universal vaccination period 2011–2013 | 208 | 40531 | 5.1 (4.4–5.9) | 56 | 1.4 (1.1–1.8) | 2505 | 682 | |
| Absolute reduction between the pre and universal vaccination periods | 77 | 2386 Growth | 2.3 (1.2–3.5) | 27 | 0.8 (0.2–1.0) | 891 (−514 − 1694)** | 297 (−12 − 567)** | |
| Percent reduction between the pre and universal vaccination periods§ | 27% | 6.3% growth | 31% (17%–82%) | 32% | 37% (9%–65%) | 26% (−25% − 42%)** | 30% (−2% − 41%) |
The number of children aged 0–11 and 12–23 was estimated by division of the number of children aged 0–59 months by 5, this estimate was multiplied by 3 to reach the number of children aged 24–59 months.
Calculated as follows: [(Annual average in period 1 - annual average in period 2) / annual average in period 1]*100.
Where period 1 is the period preceding vaccination; and period 2 is the period of universal vaccination.
In parenthesis presented are the 95 confidence intervals.
RV: rotavirus, AGE: acute gastroenteritis, CI: confidence intervals, RVGE: rotavirus gastroenteritis.
In parenthesis presented are the 5th and 95th percentiles produced by Montecarlo simulation with 100000 runs.
Estimated by weighted analysis, using the inverse of sampling fraction with weights given separately for age group (0–11, 12–23 and 24–59 months) by months and year of hospitalization.
By extrapolating the regional incidence estimates to the entire Israeli pediatric population, according to the corresponding age group.